Changfu Cheng Selected Research

1-(5-hydroxyhexyl)-3,7-dimethylxanthine

7/2016	A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.
7/2014	Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis.
1/2013	A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Changfu Cheng Research Topics

Disease

2	Diabetic Nephropathies (Diabetic Nephropathy) 07/2014 - 01/2013
1	Chronic Renal Insufficiency 07/2016

Drug/Important Bio-Agent (IBA)

3	1-(5-hydroxyhexyl)-3,7-dimethylxanthineIBA 07/2016 - 01/2013
2	Pharmaceutical PreparationsIBA 07/2016 - 01/2013
1	diethylstilbestrol monophosphate (PDES)IBA 07/2014
1	AngiotensinsIBA 07/2014
1	DeuteriumIBA 01/2013